2.90
0.07 (2.47%)
| Previous Close | 2.83 |
| Open | 2.86 |
| Volume | 2,372,525 |
| Avg. Volume (3M) | 3,168,745 |
| Market Cap | 1,007,604,992 |
| Price / Earnings (TTM) | 36.25 |
| Price / Earnings (Forward) | 5.71 |
| Price / Sales | 1.07 |
| Price / Book | 1.32 |
| 52 Weeks Range | |
| Earnings Date | 4 Nov 2025 |
| Profit Margin | 3.57% |
| Operating Margin (TTM) | 13.69% |
| Diluted EPS (TTM) | 0.070 |
| Quarterly Revenue Growth (YOY) | 2.60% |
| Quarterly Earnings Growth (YOY) | -88.60% |
| Total Debt/Equity (MRQ) | 82.71% |
| Current Ratio (MRQ) | 5.22 |
| Operating Cash Flow (TTM) | 150.72 M |
| Levered Free Cash Flow (TTM) | 74.77 M |
| Return on Assets (TTM) | 4.26% |
| Return on Equity (TTM) | 4.43% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Health Information Services (US) | Bearish | Bearish |
| Health Information Services (Global) | Bearish | Bearish | |
| Stock | GoodRx Holdings, Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | -0.5 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 1.5 |
| Technical Oscillators | -2.5 |
| Average | -0.25 |
|
GoodRx Holdings Inc is a consumer-focused digital healthcare platform that aims to lower the cost of healthcare in the United States. It operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and provides access to negotiated prices through codes that can be used to save money on prescriptions across the United States. GoodRx generates revenue from core business from pharmacy benefit managers (PBMs) that manage formularies and prescription transactions including establishing pricing between consumers and pharmacies. It also offers various healthcare products and services, including pharma manufacturer solutions, subscriptions, and telehealth services. |
|
| Sector | Healthcare |
| Industry | Health Information Services |
| Investment Style | Small Core |
| % Held by Insiders | 12.51% |
| % Held by Institutions | 62.88% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Francisco Partners Management, Lp | 30 Sep 2025 | 60,078,184 |
| Petrus Trust Company, Lta | 30 Sep 2025 | 3,098,559 |
| Technology Crossover Management X, Ltd. | 30 Sep 2025 | 1,653,566 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 6.00 (TD Cowen, 106.90%) | Buy |
| Median | 4.00 (37.93%) | |
| Low | 2.75 (Jefferies, -5.17%) | Hold |
| Average | 4.16 (43.45%) | |
| Total | 3 Buy, 4 Hold, 1 Sell | |
| Avg. Price @ Call | 2.90 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Jefferies | 22 Jan 2026 | 2.75 (-5.17%) | Hold | 2.57 |
| Citigroup | 09 Jan 2026 | 4.50 (55.17%) | Buy | 2.80 |
| Morgan Stanley | 18 Dec 2025 | 4.00 (37.93%) | Hold | 2.74 |
| Barclays | 09 Dec 2025 | 3.00 (3.45%) | Sell | 2.70 |
| JP Morgan | 11 Nov 2025 | 5.00 (72.41%) | Buy | 3.03 |
| TD Cowen | 10 Nov 2025 | 6.00 (106.90%) | Buy | 3.06 |
| Mizuho | 06 Nov 2025 | 4.00 (37.93%) | Hold | 3.16 |
| UBS | 06 Nov 2025 | 4.00 (37.93%) | Hold | 3.16 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 28 Jan 2026 | Announcement | GoodRx Announces Date for Fourth Quarter and Full Year 2025 Earnings Release and Conference Call |
| 13 Jan 2026 | Announcement | Surescripts and GoodRx Partner to Advance Patient Price Transparency |
| 08 Jan 2026 | Announcement | GoodRx Launches RxSmartSaver at Giant Eagle Pharmacies |
| 05 Jan 2026 | Announcement | GoodRx Now Offers Novo Nordisk’s Cash Price for the Launch of the Wegovy® Pill |
| 16 Dec 2025 | Announcement | GoodRx to Participate in the 44th Annual J.P. Morgan Healthcare Conference |
| 17 Nov 2025 | Announcement | GoodRx Launches New $39 Per Month Weight Loss Telemedicine Subscription, Unveils Industry-Leading Introductory Cash Price of $199 Per Month for Ozempic® and Wegovy® |
| 17 Nov 2025 | CNBC | Novo Nordisk cuts direct-to-consumer prices for Wegovy, Ozempic to $349 a month |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |